U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07899099) titled 'Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer' on Sept. 06.
Brief Summary: This prospective, real-world observational registry study will evaluate the effectiveness and safety of mecapegfilgrastim for the prevention of chemotherapy-induced neutropenia in patients with advanced breast cancer receiving chemotherapy. The decision to use mecapegfilgrastim will be made by the treating physician as part of routine clinical care. Participants will be followed to collect information on neutropenia, febrile neutropenia, treatment-related adverse events, and chemotherapy delivery.
Study Start ...